Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
858 Therapeutics' PARG inhibitor gets second fast-track award for breast cancer
16+ hour, 19+ min ago (383+ words) AllSci San Diego-based 858 Therapeutics announced receipt of US FDA Fast Track Designation for ETX-19477, an oral poly(ADP-ribose) glycohydrolase (PARG) inhibitor, for the treatment of adult patients with BRCA-mutated, hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), unresectable…...
Pathos AI gains co-exclusive rights to AstraZeneca's ERα PROTAC for ER+ breast cancer
2+ week, 1+ day ago (67+ words) The deal is the second partnership between Pathos and AstraZeneca. The two companies previously partnered with Tempus AI (Nasdaq: TEM), on a multi-year collaboration to build a multimodal oncology foundation model. Access the AllSci platform to explore the science behind…...
Roche partners with Evexta Bio to test dual-node inhibitor against resistant breast cancer
2+ week, 1+ day ago (99+ words) The Phase Ib study will evaluate the safety, tolerability and preliminary anti-tumor activity of the combination in at least 15 patients, with study initiation targeted for Q4 2026. The collaboration marks Evexta Bio's first clinical agreement involving rupitasertib. The company was founded by…...
CSPC's HER2 Antibody Wins China Breakthrough Designation
1+ mon, 5+ day ago (688+ words) AllSci CSPC Pharmaceutical Group Limited (HKEX: 01093) announced that China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to both docetaxel for injection (albumin-bound) (HB1801) and anbenitamab (KN026), a HER2-targeted bispecific antibody, for use in combination as first-line treatment of unresectable…...